4 cytundeb, rhan amser, swydd yn Chesterton, Cambridge
Hyderus o ran Anabledd
Gweithio o bell
Lleoliad
- UK
- Eastern England
- Cambridgeshire
- Cambridge
- Chesterton (4)
Dyddiad hysbysebu
Categori
Math o gytundeb
Oriau
Mewngofnodwch nawr i greu rhybudd e-bost a derbyn y swyddi diweddaraf ar gyfer y chwiliad hon yn syth i'ch e-bost
MewngofnodiSales Associate - H. Samuel - Temporary - Part Time
- 18 June 2024
- Signet Jewelers - Cambridge, CB2 3NA
- Competitive salary plus bonuses, benefits & staff discount
- Cytundeb
- Rhan amser
Our Sales Associates help our customers Celebrate Life & Express Love Temporary Sales Associate - Part Time Our store teams are made up of customer-first people with a real passion for outstanding service, creating amazing experiences and lasting memories for ...
Flexible Nursery Practitioner
- 17 June 2024
- Kindred Education Ltd - Cambridgeshire, CB4 3EP
- £11.44 to £11.50 per hour
- Cytundeb
- Rhan amser
JOIN THE UK'S NUMBER 1 NURSERY GROUP Are you an inspiring and caring individual interested to work according to your personal schedule? If so, a Flexible Nursery Practitioner role could be for you Working in a winning nursery, voted the UK's top nursery group ...
Flexible Nursery Practitioner
- 07 June 2024
- Kindred Education Ltd - Cambridgeshire, CB4 3EP
- £11.44 to £11.50 per hour
- Cytundeb
- Rhan amser
JOIN THE UK'S NUMBER 1 NURSERY GROUP Are you an inspiring and caring individual interested to work according to your personal schedule? If so, a Flexible Nursery Practitioner role could be for you Working in a winning nursery, voted the UK's top nursery group ...
Fractional CSO/Advisor - mRNA biotech
- 03 June 2024
- Hays Specialist Recruitment - Cambridge, Cambridgeshire, CB2 0AA
- £2,000.0 to £2,400.0 per day
- £200-300 per hour
- Yn gyfan gwbl o bell
- Cytundeb
- Rhan amser
Your new company You will be joining a breakthrough VC backed biotech who have recently raised a multi-million pound Seed funding round.They are pioneering novel treatments in the field of cancer immunoprevention and are currently developing a lead mRNA ...
- 1